Edwards Lifesciences Corp Earnings Summary — Q1 2026
Edwards Lifesciences Delivers Record Revenue and Double-Digit Organic Growth in Q1 2026
Key Takeaways
- Revenue grew 16.7% year-over-year to $1.65 billion, marking a significant acceleration from previous quarters.
- Operating income rebounded sharply to $477.6 million after a depressed Q4 2025, supported by lower SG&A and R&D relative to total revenue.
- The company continues to maintain a highly conservative capital structure with zero long-term debt noted in management commentary.
- Net income to common shareholders reached $380.7 million, showing steady 6.34% growth above the prior year's adjusted figures.
- Earnings quality is bolstered by the divestiture of the non-core Critical Care business, focusing efforts on high-growth structural heart therapies.
- Shareholder dilution is minimal, with basic shares outstanding decreasing 1.21% YoY to 579 million due to ongoing buyback programs.
Management Guidance
Management remains focused on expanding the TAVR market and pivoting into transcatheter therapies for mitral and tricuspid valve disease, aiming for consistent high-quality compounding growth.
Sentiment Shift
Improving
Outlook
The outlook is robust as the company leverages its massive installation base and high switching costs to defend its TAVR dominance while innovating in structural heart therapies.
← Back to Edwards Lifesciences Corp AI analysis
Unlock the full report
Deep-dive sections, financial charts, AI chat and PDF export are available with Premium.
This summary is AI-generated from Edwards Lifesciences Corp's latest annual report and public disclosures. It is for informational purposes only and is not investment advice.